Analysguiden: "Broadening the portfolio"
We are raising our sales assumptions and the likelihood of approval (LOA) of the PREVENT-nCoV project. We see the AV001 advancing towards clinical trials and becoming an important value driver in the long term. These adjustments compensate by a small margin the close to doubling in number of shares following the proposed new share issue. Our summation of the various project values in the company amounts to SEK 24 in a ‘base case’.Deal with Adaptvac reduces portfolio risk ExpreS2ion is broadening its portfolio by exercising an option from its partner Adaptvac to take control of full